Ozmosi | Nicorandil Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Nicorandil

Pronounced as: nye-KOR-an-dil

Alternative Names: nicorandil, sigmart
Clinical Status: Active
Latest Update: 2025-08-24
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Potassium Channel Opener

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral, Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Bangladesh | Denmark | Dominican Republic | Egypt | France | Germany | India | Ireland | Italy | Japan | Korea | Lebanon | Malta | Netherlands | New Zealand | Pakistan | Peru | Portugal | Russia | Saudi Arabia | Slovenia | Sri Lanka | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Merck KGaA
Company Location:
Company Founding Year: 1668
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nicorandil

Countries in Clinic: China

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

Highest Development Phases

Phase 1: Angina Pectoris|Healthy Volunteers

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

CTR20250760

 CTR20250760

P1

Completed

Angina Pectoris

2025-04-09

2025-11-23

Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status

CTR20231963

 CTR20231963

P1

Completed

Healthy Volunteers

2023-06-01

2025-04-29

CTR20230455

 CTR20230455

P1

Completed

Angina Pectoris

2023-03-23

2025-04-29

Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status

Recent News Events

Date

Type

Title

10/28/2024

News Article

 Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024

10/09/2024

News Article

 Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers

05/13/2024

PubMed

 Nicorandil mitigates arsenic trioxide-induced lung injury via modulating vital signalling pathways SIRT1/PGC-1alpha/TFAM, JAK1/STAT3, and miRNA-132 expression.

04/23/2024

PubMed

 Purinergic inhibitory regulation of esophageal smooth muscle is mediated by P2Y receptors and ATP-dependent potassium channels in rats.

03/31/2024

PubMed

 Therapeutic potential of nicorandil beyond anti-anginal drug: A review on current and future perspectives.

02/27/2023

News Article

 Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings

01/05/2023

News Article

 Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions